Market news

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.27% on an annualized basis producing an average annual return of 19.81%. Currently, Vertex Pharmaceuticals has a market

This biotech player is firing on all cylinders.

On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]

And there could be more positive developments ahead.

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $574.78,

Vertex Pharmaceuticals reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.

This company has had plenty of setbacks in recent years, but it generally bounces back.

Vertex Pharmaceuticals (VRTX) has been in focus after presenting at the 18th Annual Boston C-Level Technology Leadership Summit on September 10, where its Chief Digital and Information Officer outlined the group’s technology priorities. Recent trading has been choppy for Vertex Pharmaceuticals, with the share price falling 4.9% over the past week but still showing a 14.6% 90 day share price return and a 32.1% 1 year total shareholder return. This points to momentum that has built over a...

Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s priorities, CEO and President Reshma Kewalramani said at Morgan Stanley’s 24th Annual Healthcare Conferen

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers.

The company has tremendous prospects.

Motley Fool Press Release.

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...

How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year. Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price...

BOSTON, September 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification.

Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.

Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.